26.02.2024 • NewsArkemaRenewable EnergySustainability

Arkema Signs Green Energy Supply Deals for US Sites

Arkema has signed long term renewable energy agreements for its US sites in Calvert City, Kentucky, Beaumont, Texas, Chatham, Virginia, and West Chester, Pennsylvania, as well as for all Bostik sites in the United States. The company said that these agreements are part of its climate plan.

By 2024, Arkema expects to obtain approximately 40% of the power needed to run its US operations from renewable sources after signing deals with energy providers Tennessee Valley Authority (TVA), Entergy and 3Degrees. This is a major milestone in the group’s decarbonization goal to reduce its Scopes 1 and 2 greenhouse gas emissions by 48.5% by 2030 versus 2019, Arkema said.

TVA and Entergy are expected to supply, respectively, an estimated 35 GWh/year and 60 GWh/year of electricity from solar energy to Calvert City and Beaumont. 3Degrees is expected to supply green e-certified renewable electricity certificates for the decarbonization of approximately 57 GWh/year of electricity for the Chatham and West Chester sites, as well as for all Bostik facilities in the United States.

Arkema had previously signed other renewable energy supply deals for its sites in Clear Lake and Bayport, Texas.

© NikiforTodorov/Shutterstock
© NikiforTodorov/Shutterstock

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.